Daniela Castro: Impact of insurance status on survival outcomes in patients with mRCC
Daniela Castro, Clinical Research Associate of Medical Oncology at City of Hope, shared a post on X about a paper she co-authored with colleagues published in JCO Oncology Advances:
“Impact of Insurance Status on Survival Outcomes in Patients With Metastatic Renal Cell Carcinoma”
Authors: Daniela Castro, Georges Gebrael, Luis Meza, Xiaochen Li, Nishita Tripathi, JoAnn Hsu, Errol Philip, Cristiane Bergerot, Neeraj Agarwal, Sumanta Pal et al.
“Newly published in JCO Oncology Advances! Our study explores how insurance status affects survival outcomes for patients with metastatic renal cell carcinoma (mRCC) receiving first-line systemic therapy.
Study Context:
Previous research suggests that insurance status can influence cancer treatment and survival outcomes. We assessed data from 645 patients at two cancer centers, grouped by primary and secondary insurance status.
Key Findings:
Medicare patients had significantly better progression-free survival (PFS) compared to those with Medicaid/no insurance (HR 0.698). Private insurance showed no significant PFS difference compared to Medicaid/no insurance (HR 1.017).
Overall Survival (OS):
Medicare patients had a significantly lower risk of death compared to those with Medicaid/no insurance (HR 0.495), while OS was similar between the private insurance and Medicaid/no insurance groups (HR 0.955).
Secondary insurance improved PFS but did not impact OS.
Conclusion:
In patients treated with first-line systemic therapies for mRCC, Medicare and secondary insurance were associated with better survival outcomes and improved PFS, respectively. These findings provide valuable insights to inform future healthcare policy.
Huge thank you to my incredible mentors, Sumanta Pal, Neeraj Agarwal for the opportunity to lead this project and to all our amazing co-authors for their invaluable contributions to these data.”
Read articles on kidney cancer:
“Kidney Cancer: Symptoms ,Causes, Stages, Diagnosis and Treatment”
“Renal Cell Carcinoma in Adults: What patients should know about”
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023